Therapeutic Mechanisms Of Classic Hallucinogens In The Treatment Of Addictions: From Indirect Evidence To Testable Hypotheses.
Michael P. Bogenschutz, Jessica M Pommy
Published 2012 · Medicine, Chemistry
Download PDFAnalyze on Scholarcy
Alcohol and drug addiction are major public health problems, and existing treatments are only moderately effective. Although there has been interest for over half a century in the therapeutic use of classic hallucinogens to treat addictions, clinical research with these drugs was halted at an early stage in the early 1970s, leaving many fundamental questions unanswered. In the past two decades, clinical research on classic hallucinogens has resumed, although addiction treatment trials are only now beginning. The purpose of this paper is to provide a targeted review of the research most relevant to the therapeutic potential of hallucinogens, and to integrate this information with current thinking about addiction and recovery. On the basis of this information, we present a heuristic model which organizes a number of hypotheses that may be tested in future research. We conclude that existing evidence provides a convincing rationale for further research on the effects of classic hallucinogens in the treatment of addiction.
This paper references
A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment.
D I Kabel (1996)
The experimental use of psychedelic (LSD) psychotherapy.
Walter N. Pahnke (1970)
The effects of psychedelic (LSD) therapy on values, personality, and behavior.
Catharine H. Savage (1966)
Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial.
Jack R. Cornelius (1997)
Wilbourne. Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders
P.L.W.R. Miller (2002)
Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review
Romualdas Mačiulaitis (2008)
Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors
Sungho Maeng (2008)
Psilocybin in smoking cessation: A pilot study
M. W. Johnson (2010)
Alcoholics Anonymous and Other 12-Step Groups
Chad D. Emrick (1999)
Five-Factor Model personality profiles of drug users
Antonio Terracciano (2008)
Serotonin and alcohol intake, abuse, and dependence: Findings of animal studies
David Lemarquand (1994)
Antidepressant effects of ketamine in depressed patients
Robert M. Berman (2000)
Peyote Religion: A History
Omer Call Stewart (1987)
Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis.
Marta Torrens (2005)
Prehistoric peyote use: alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas.
Hesham R El-Seedi (2005)
A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetmine in alcoholics.
Leo E. Hollister (1969)
Psychedelic Drug (DPT)-Assisted Psychotherapy with Alcoholics: A Controlled Study
John C. Rhead (1977)
Drug craving and addiction: integrating psychological and neuropsychopharmacological approaches
Ingmar H. A. Franken (2003)
Life-Changing Experiences, Spirituality and Religiousness of Persons Entering Treatment for Alcohol Problems
Elizabeth A. R. Robinson (2003)
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later
Roland R Griffiths (2008)
Imaging stress- and cue-induced drug and alcohol craving: association with relapse and clinical implications.
Rajita Sinha (2007)
In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents.
Marta Puig (2003)
W. A. Richards (2012)
Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: a follow-up study.
Walter T. Bowen (1970)
Single Versus Repeated Sessions of Ketamine-Assisted Psychotherapy for People with Heroin Dependence
Evgeny Krupitsky (2007)
5-HT Modulation of Dopamine Release in Basal Ganglia in Psilocybin-Induced Psychosis in Man—A PET Study with [11C]raclopride
Franz X. Vollenweider (1999)
Spiritual Well-Being: Conceptualization and Measurement
Craig W. Ellison (1983)
Cocaine craving as a predictor of treatment attrition and outcomes after residential treatment for cocaine dependence.
Damaris J. Rohsenow (2007)
A review of the acute subjective effects of MDMA/ecstasy.
Chelsea A. Baylen (2006)
Possible pharmacological probes for predicting and preventing relapse in treated alcoholics.
Naranjo Ca (1991)
Ondansetron reduces the craving of biologically predisposed alcoholics
Bankole A Johnson (2002)
Joan P. Avis (1982)
Serotonin uptake inhibitors attenuate ethanol intake in problem drinkers.
Claudio A. Naranjo (1989)
Behavioral Tolerance to Lysergic Acid Diethylamide is Associated with Reduced Serotonin-2A Receptor Signaling in Rat Cortex
Paul J Gresch (2005)
Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain.
Neil S. Buckholtz (1990)
Prevalence and Co-occurrence of Substance Use Disorders and Independent Mood and Anxiety Disorders: Results From the National Epidemiologic Survey on Alcohol and Related Conditions
John A. Talbott (2006)
Examining the effects of alcoholism typology and AA attendance on self-efficacy as a mechanism of change.
Michael P. Bogenschutz (2006)
‘Hitting Highs at Rock Bottom’: LSD Treatment for Alcoholism, 1950–1970
Erika Dyck (2006)
A role for spiritual change in the benefits of 12-step involvement.
Sarah E. Zemore (2007)
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Teri Suzanne Krebs (2012)
Personality change in LSD users.
John Bottrill (1969)
A program for treatment of alcoholism: LSD
A. Hoffer (1967)
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Carlos A. Zarate (2006)
A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers
Glenn J. H. Dumont (2006)
The psychedelic experience--a new concept in psychotherapy.
John Neil Sherwood (1962)
Lysergide treatment of schizophrenic and nonschizophrenic alcoholics: a controlled evaluation.
Milan Tomsovic (1970)
What is motivational interviewing? Behav
S. Rollnick (1995)
Personality change associated with psychedelic (LSD) therapy: A preliminary report.
Robert E. Mogar (1964)
Alcohol Involvement and the Five-Factor Model of Personality: A Meta-Analysis
John M Malouff (2007)
Development of novel medications for drug addiction. The legacy of an African shrub.
Stanley D. Glick (2000)
Personality Changes in Women Recovering from Substance-Related Dependence
Patricia D. Borman (2006)
Varieties of Religious Experience
William James (1990)
The Construction and Preliminary Validation of a Measure of Reported Mystical Experience
Ralph W. Jr Hood (1975)
From In-Session Behaviors to Drinking Outcomes: A Causal Chain for Motivational Interviewing
Richard J. Frances (2011)
Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse.
George R. Breese (2011)
Agonist-directed signaling of the serotonin 2A receptor depends on β-arrestin-2 interactions in vivo
Cullen L. Schmid (2008)
Efficacy of buspirone in alcohol dependence: a review.
T Malec (1996)
Assessment of addiction severity among ritual users of ayahuasca.
Josep María Fábregas (2010)
Cracking the Plaster Cast: Big Five Personality Change during Intensive Outpatient Counseling
Ralph L. Piedmont (2001)
Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up.
Evgeny Krupitsky (2002)
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
Bankole A Johnson (2008)
A review of LSD treatment in alcoholism.
Faruk S. Abuzzahab (1971)
Effects of lowered serotonin transmission on cocaine-induced striatal dopamine response: PET [¹¹C]raclopride study in humans.
Sylvia M. L. Cox (2011)
The adverse effects of hallucinogens from intramural perspective.
Ede Frecska (2006)
Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons
Gary A. Gudelsky (2008)
Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament.
John H. Halpern (2008)
Pharmacology of classical hallucinogens and related designer drugs
R. A. Glennon (2009)
Medications and Alcohol Craving
R. M. Swift (1999)
Human hallucinogen research: guidelines for safety
M A Johnson (2008)
Positive autoregulation of GDNF levels in the ventral tegmental area mediates long-lasting inhibition of excessive alcohol consumption
S Barak (2011)
The relationship of NEO-PI performance to coping styles, patterns of use, and triggers for use among substance abusers.
Richard A. McCormick (1998)
Family History of Alcohol Dependence and Initial Antidepressant Response to an N-methyl-D-aspartate Antagonist
Laura E. Phelps (2009)
5-HT receptors and reward-related behaviour: A review
Dave J. Hayes (2011)
Amanda White Gibson (2000)
LONG LASTING EFFECTS OF LSD ON NORMALS
William H. Mcglothlin (1967)
Mysticaltype experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months
R. Griffiths (2008)
Motivation for Change and Alcoholism Treatment
Carlo C. Diclemente (1999)
Ketamine and the potential role for rapid-acting antidepressant medications.
John H. Krystal (2007)
GDNF--a potential target to treat addiction.
Sebastien Carnicella (2009)
Exploratory findings from the Reasons for Drinking Questionnaire.
William H. Zywiak (2003)
Identifying the neural circuitry of alcohol craving and relapse vulnerability.
Andreas Heinz (2009)
Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior
Javier González-Maeso (2007)
My First Forty Years
B. Wilson (2000)
The phenomenon of quantum change.
William R. Miller (2004)
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
Marije aan het Rot (2010)
Psychedelic Drugs Reconsidered
James B. Bakalar (1979)
Religion and Psychoactive Sacraments: A Bibliographic Guide
T. B. Roberts (1995)
Impact of different personality dimensions (NEO Five-Factor Inventory) on the outcome of alcohol-dependent patients 6 and 12 months after treatment
Miriam Bottlender (2005)
Comorbidity and temporal ordering of alcohol use disorders and other psychiatric disorders: results from a Danish register-based study.
Trine Flensborg-Madsen (2009)
Relationship between craving and personality in treatment-seeking women with substance-related disorders
Monica L. Zilberman (2003)
Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking.
Bankole A Johnson (2011)
Investigating the Mechanisms of Hallucinogen-Induced Visions Using 3,4-Methylenedioxyamphetamine (MDA): A Randomized Controlled Trial in Humans
Matthew J. Baggott (2010)
Life Changing Experiences: An Analysis of 21st Century Martin Amis
Julia van Luijk (2011)
Alcohol treatment, changes in coping skills, self-efficacy, and levels of alcohol use and related problems 1 year following treatment initiation.
Stephen A. Maisto (2000)
Religion and Psychoactive Sacraments: A Bibliographic Guide
T. B. Roberts (1995)
The Olivocerebellar Projection Mediates Ibogaine-Induced Degeneration of Purkinje Cells: A Model of Indirect, Trans-Synaptic Excitotoxicity
Elizabeth E O'Hearn (1997)
Jesus, peyote, and the holy people: alcohol abuse and the ethos of power in Navajo healing.
J F Garrity (2000)
The role of glutamate in mood disorders: Results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects
Sungho Maeng (2007)
Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression
Rebecca B. Price (2009)
Mysticism and Philosophy.
Ninian Smart (1960)
The Combination of Psychedelic and Aversive Approaches in Alcoholism Treatment
E. M. Krupitsky (1992)
Mescaline, LSD, Psilocybin, and Personality Change a Review†
Sanford M. Unger (1963)
Serotonin, But Not N-Methyltryptamines, Activates the Serotonin 2A Receptor Via a β-Arrestin2/Src/Akt Signaling Complex In Vivo
Cullen L. Schmid (2010)
Bissoondial Ootim (2000)
Medication development of ibogaine as a pharmacotherapy for drug dependence.
Deborah C. Mash (1998)
Role of the serotonergic system in alcohol dependence: from animal models to clinics.
Youssef Sari (2011)
Temporal sequencing of lifetime mood disorders in relation to comorbid anxiety and substance use disorders
Ron de Graaf (2003)
DPT as an adjunct in psychotherapy of alcoholics.
S Grof (1973)
Linking "big" personality traits to anxiety, depressive, and substance use disorders: a meta-analysis.
Roman Kotov (2010)
Cognitive consequences of forced compliance.
Leon Festinger (1959)
Hallucinogenic drugs and plants in psychotherapy and shamanism.
Rebecca Metzner (1998)
Changes in Spirituality Among Ayahuasca Ceremony Novice Participants
Stephen Trichter (2009)
LSD IN PSYCHOTHERAPY.
Seymour Schoen (1964)
Theroetical aspects of LSD therapy
J. Buckman (1967)
Self-Efficacy: The Exercise of Control
Albert Bandura (1997)
Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype.
Helen M. Pettinati (2000)
Serotonin (5-HT) induces glial cell line-derived neurotrophic factor (GDNF) mRNA expression via the transactivation of fibroblast growth factor receptor 2 (FGFR2) in rat C6 glioma cells.
Mami Tsuchioka (2008)
Determining the relative importance of the mechanisms of behavior change within Alcoholics Anonymous: a multiple mediator analysis.
John F Kelly (2012)
Relations between personality and coping: a meta-analysis.
Jennifer K Connor-Smith (2007)
A controlled study of lysergide in the treatment of alcoholism. 1. The effects on drinking behavior.
Reginald George Smart (1966)
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Roland R Griffiths (2011)
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
Francisco A. Moreno (2006)
Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis.
Edward V Nunes (2004)
Pierre Cochat (2012)
Brain dopamine response in human opioid addiction.
Mark R. C. Daglish (2008)
Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex
Jean-Claude Béı̈que (2007)
Dynamic effects of craving and negative affect on adolescent smoking relapse.
Rinka M P van Zundert (2012)
De profundis: spiritual transformations in Alcoholics Anonymous.
Alyssa A. Forcehimes (2004)
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.
Franz X. Vollenweider (1998)
Reactivity to laboratory stress provocation predicts relapse to cocaine.
Sudie E Back (2010)
Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems.
Claudio A. Naranjo (1995)
Treatment of alcoholism using psychedelic drugs: a review of the program of research.
Mariavittoria Mangini (1998)
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.
Sanjay J Mathew (2010)
A Comparison of General Self-Efficacy and Drinking Refusal Self-Efficacy in Predicting Drinking Behavior
Tian Po Oei (2007)
Ketamine Enhanced Psychotherapy: Preliminary Clinical Observations on Its Effectiveness in Treating Alcoholism
Eli Kolp (2006)
The Use of Hallucinogens in the Treatment of Addiction
John H. Halpern (1996)
Glial Cell Line-Derived Neurotrophic Factor
Fluoxetine attenuates alcohol intake and desire to drink.
Claudio A. Naranjo (1994)
Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists
José L. Moreno (2011)
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Franz X. Vollenweider (2010)
REACTIONS TO PSILOCYBIN ADMINISTERED IN A SUPPORTIVE ENVIRONMENT.
Timothy J. C. Leary (1963)
The Role of Religion, Spirituality and Alcoholics Anonymous in Sustained Sobriety
Lee Ann Kaskutas (2003)
A consensus statement on defining change talk
W. R. Miller (2006)
B. Meyerhoff (1974)
A clinical study of LSD treatment in alcoholism.
Annick Ludwig (1969)
Relationship of relapse with impulsivity, novelty seeking and craving in male alcohol-dependent inpatients.
Cuneyt Evren (2012)
Treatment of cocaine dependence and depression
Bruce J. Rounsaville (2004)
Report on Psychoactive Drug Use Among Adolescents Using Ayahuasca Within a Religious Context
Evelyn Doering-Silveira (2005)
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
Charles S. Grob (2011)
Psychological and Cognitive Effects of Long-Term Peyote Use Among Native Americans
John H. Halpern (2005)
Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling
Kelly A Jones (2009)
Heterogeneous effects of alcohol on dopamine release in the striatum: a PET study.
Karmen K. Yoder (2007)
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness
Katherine A. MacLean (2011)
The role of serotonin in craving: from basic research to human studies.
Roberto Ciccocioppo (1999)
Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study.
Cathy Savage (1973)
Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers.
Claudio A. Naranjo (1992)
Traditional Medicine in the Treatment of Drug Addiction
Lin Lu (2009)
A measure of religious background and behavior for use in behavior change research
Gerard J. Connors (1996)
Self-efficacy: Toward a unifying theory of behavioral change
Albert Bandura (1978)
The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence.
Edward J. Khantzian (1987)
Moderating effects of a craving intervention on the relation between negative mood and heavy drinking following treatment for alcohol dependence.
Katie A Witkiewitz (2011)
A. Bandura (1994)
Role of BDNF and GDNF in drug reward and relapse: A review
Udi E. Ghitza (2010)
The role of self-efficacy in the treatment of substance use disorders.
Ronald M. Kadden (2011)
Spirituality in recovery: a lagged mediational analysis of alcoholics anonymous' principal theoretical mechanism of behavior change.
John F Kelly (2011)
Psychedelic drugs and mystical experience.
Walter N. Pahnke (1969)
Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial.
Bankole A Johnson (2000)
A personality-based description of maturing out of alcohol problems: extension with a five-factor model and robustness to modeling challenges.
Andrew K Littlefield (2010)
Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration.
Sebastien Carnicella (2010)
Five Factor correlates: A comparison of substance abusers and non-substance abusers
C. Dubey (2010)
Motivation for Change: Implications for Substance Abuse Treatment
Carlo C. Diclemente (1999)
GDNF is a fast-acting potent inhibitor of alcohol consumption and relapse
James C. Ballenger (2009)
Peyote in the treatment of alcoholism among American Indians.
B J Albaugh (1974)
AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes
Ce Zhang (2008)
Craving and relapse measurement in alcoholism.
Annelize Potgieter (1999)
Daily ratings measures of alcohol craving during an inpatient stay define subtypes of alcohol addiction that predict subsequent risk for resumption of drinking.
David Oslin (2009)
Big Five factors of personality and replicated predictions of behavior.
S. V. Paunonen (2003)
Negative affect, relapse, and Alcoholics Anonymous (AA): does AA work by reducing anger?
John F Kelly (2010)
Sociodemographic and psychopathologic predictors of first incidence of DSM-IV substance use, mood and anxiety disorders: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions
Bridget F. Grant (2009)
The behavioral pharmacology of hallucinogens.
William E Fantegrossi (2008)
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
Roland R Griffiths (2006)
Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical cons
Walter N. Pahnke (1963)
Present state of psycholytic therap y and its possibilities
H. Leuner (1967)
Psychedelics and the Human Receptorome
Thomas S. Ray (2010)
Drinking Careers: A Twenty-Five-Year Study of Three Navajo Populations
Paul G. Spicer (1996)
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Nancy Diazgranados (2010)
5-HT2A Receptor-Mediated Regulation of Brain-Derived Neurotrophic Factor mRNA in the Hippocampus and the Neocortex
Vidita A Vaidya (1997)
The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study
Michael C. Mithoefer (2011)
This paper is referenced by
Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision
Peter Schuyler Hendricks (2014)
Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada.
Gerald V. Thomas (2013)
Classic hallucinogens in the treatment of addictions
Michael P. Bogenschutz (2016)
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Michael P. Bogenschutz (2015)
Classic hallucinogens in the treatment of addictions F
Michael P. Bogenschutz (2015)
5-HT2B Receptor-mediated Cardiac Valvulopathy
Pallavi Nistala (2018)
Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives.
Simon D Brandt (2017)
The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women
Elena Argento (2018)
Psychedelic therapy as a complementary treatment approach for alcohol use disorders
Peter Eischens (2018)
Therapeutic Applications of Classic Hallucinogens.
Michael P. Bogenschutz (2018)
Predicting Responses to Psychedelics: A Prospective Study
E. Haijen (2018)
Neurociencias y aplicaciones psicoterapéuticas en el renacimiento de la investigación con psicodélicos Neurosciences and psycotherapeutic applications in the psychedelic research renaissaince
Sandra Timmermann (2014)
Can psychedelic compounds play a part in drug dependence therapy?
Ben Sessa (2015)
Keywords Psilocybin ! Hallucinogens ! Meditation ! Mystical experiences ! Neural model ! Default mode network ! Medial prefrontal cortex !
Frederick Streeter Barrett (2017)
Lysergic acid diethylamide: a drug of ‘use’?
Saibal Das (2016)
A review of lysergic acid diethylamide (LSD) in the treatment of addictions: historical perspectives and future prospects.
Mitchell B. Liester (2014)
Exploring the Therapeutic Potential of Psychedelics
Xavier Martínez Hernández (2018)
Therapeutic Induction of Altered States of Consciousness: Investigation of 1-20Hz Neurofeedback
Heather Hargraves (2017)
Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use
Zach Walsh (2016)
Exploring ayahuasca-assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada.
Elena Argento (2019)
Geschichte der Psychedelika in der Medizin
Ben Sessa (2018)
A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment
Brittany Vasae Burdick (2013)
Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.
Albert Garcia-Romeu (2014)
The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging
Rafael Guimarães Dos Santos (2016)
Cessation and reduction in alcohol consumption and misuse after psychedelic use
Albert Garcia-Romeu (2019)
The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens
Clinton E. Canal (2017)
Psilocybin-assisted treatment for alcohol dependence
Michael P. Bogenschutz (2016)
Psychedelics and the new behaviourism: considering the integration of third-wave behaviour therapies with psychedelic-assisted therapy
Zach Walsh (2018)
Effects of ayahuasca on the development of ethanol-induced behavioral sensitization and on a post-sensitization treatment in mice
A J Oliveira-Lima (2015)
Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts
Tehseen Noorani (2018)
Why MDMA therapy for alcohol use disorder? And why now?
Ben Sessa (2018)
Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness
Matthias Forstmann (2017)See more